|AstraZeneca’s potential $3 billion cancer pill wins early approval|
|By Ben Hirschler - REUTERS|
|Saturday, 14 November 2015 03:45|
A new lung cancer pill from AstraZeneca , designed for patients whose disease has worsened after treatment with other therapies, won early U.S. approval on Friday, in a boost for the British drugmaker.
Tagrisso, also known as AZD9291, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on older drugs. During its defense against a takeover attempt by Pfizer last year, the firm forecast the drug could eventually sell as much as $3 billion a year.